Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus

Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus 714 Original article Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus Hironobu Tsukamoto, Satoshi Tanida, Tsutomu Mizoshita, Keiji Ozeki, Masahide Ebi, Takaya Shimura, Yoshinori Mori, Hiromi Kataoka, Takeshi Kamiya and Takashi Joh Objective Infliximab and tacrolimus are effective for the tacrolimus nonresponders. No serious adverse events treatment of patients with moderate or severe were encountered. corticosteroid-dependent/refractory ulcerative colitis. Conclusion Infliximab salvage therapy following However, regarding treatment for these patients, whether tacrolimus tended to appear more efficacious in tacrolimus tacrolimus therapy should precede infliximab as a second- responders (loss of response or no tolerance) than in line therapy remains controversial. To address this issue, nonresponders (refractoriness), although nonresponders we retrospectively investigated the efficacy of infliximab also achieved satisfactory results. Sequential therapy may salvage therapy for patients with severe or moderate thus prove useful and well tolerated. In addition, we should ulcerative colitis who failed to respond to tacrolimus. avoid missing the proper timing of colectomy, and care is Methods We assessed clinical backgrounds and warranted regarding adverse events. Eur J Gastroenterol therapeutic outcomes at baseline, 8, and 30 weeks for Hepatol 25:714–718 2013 Wolters Kluwer Health | 13 patients receiving infliximab for severe or http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Gastroenterology & Hepatology Wolters Kluwer Health

Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus

Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/infliximab-salvage-therapy-for-patients-with-ulcerative-colitis-who-ZneXruRPZh

References (16)

Copyright
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
ISSN
0954-691X
eISSN
1473-5687
DOI
10.1097/MEG.0b013e32835eb999
pmid
23411870
Publisher site
See Article on Publisher Site

Abstract

714 Original article Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus Hironobu Tsukamoto, Satoshi Tanida, Tsutomu Mizoshita, Keiji Ozeki, Masahide Ebi, Takaya Shimura, Yoshinori Mori, Hiromi Kataoka, Takeshi Kamiya and Takashi Joh Objective Infliximab and tacrolimus are effective for the tacrolimus nonresponders. No serious adverse events treatment of patients with moderate or severe were encountered. corticosteroid-dependent/refractory ulcerative colitis. Conclusion Infliximab salvage therapy following However, regarding treatment for these patients, whether tacrolimus tended to appear more efficacious in tacrolimus tacrolimus therapy should precede infliximab as a second- responders (loss of response or no tolerance) than in line therapy remains controversial. To address this issue, nonresponders (refractoriness), although nonresponders we retrospectively investigated the efficacy of infliximab also achieved satisfactory results. Sequential therapy may salvage therapy for patients with severe or moderate thus prove useful and well tolerated. In addition, we should ulcerative colitis who failed to respond to tacrolimus. avoid missing the proper timing of colectomy, and care is Methods We assessed clinical backgrounds and warranted regarding adverse events. Eur J Gastroenterol therapeutic outcomes at baseline, 8, and 30 weeks for Hepatol 25:714–718 2013 Wolters Kluwer Health | 13 patients receiving infliximab for severe or

Journal

European Journal of Gastroenterology & Hepatology – Wolters Kluwer Health

Published: Jun 1, 2013

There are no references for this article.